A detailed history of Wellington Management Group LLP transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Wellington Management Group LLP holds 5,695,699 shares of IONS stock, worth $271 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,695,699
Holding current value
$271 Million
% of portfolio
0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$42.03 - $53.55 $239 Million - $305 Million
5,695,699 New
5,695,699 $247 Million
Q4 2023

Feb 12, 2024

BUY
$43.39 - $51.63 $200 Million - $238 Million
4,616,978 New
4,616,978 $234 Million
Q3 2023

Nov 14, 2023

BUY
$38.5 - $47.13 $32.6 Million - $39.9 Million
845,902 Added 92.48%
1,760,625 $79.9 Million
Q2 2023

Aug 14, 2023

BUY
$34.73 - $43.33 $31.8 Million - $39.6 Million
914,723 New
914,723 $37.5 Million
Q1 2022

May 16, 2022

SELL
$29.88 - $37.04 $392,443 - $486,483
-13,134 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$25.61 - $35.1 $336,361 - $461,003
13,134 New
13,134 $399,000
Q3 2021

Nov 15, 2021

SELL
$33.54 - $40.55 $198,254 - $239,691
-5,911 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$34.54 - $47.25 $204,165 - $279,294
5,911 New
5,911 $236,000
Q4 2020

Feb 12, 2021

SELL
$45.3 - $60.27 $39.4 Million - $52.4 Million
-868,993 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$47.45 - $62.95 $41 Million - $54.3 Million
-863,371 Reduced 49.84%
868,993 $41.2 Million
Q2 2020

Aug 14, 2020

SELL
$46.85 - $61.05 $106 Million - $138 Million
-2,252,853 Reduced 56.53%
1,732,364 $102 Million
Q1 2020

May 14, 2020

SELL
$41.6 - $63.4 $115 Million - $175 Million
-2,752,639 Reduced 40.85%
3,985,217 $188 Million
Q4 2019

Feb 11, 2020

BUY
$53.85 - $65.27 $363 Million - $440 Million
6,737,856 New
6,737,856 $407 Million

Others Institutions Holding IONS

About IONIS PHARMACEUTICALS INC


  • Ticker IONS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 141,940,992
  • Market Cap $6.76B
  • Description
  • Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...
More about IONS
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.